Older adults with colon cancer are not different from younger ones, but treated differently: Retrospective analysis from single centre

Guner Oytun, Merve/0000-0002-7417-5415; Bulut, Gulcan/0000-0001-7382-0972WOS:000634465200001PubMed: 33752476Aim Decision- making of the treatment of colon cancer for the older patients becomes more complicated in consequence of comorbidities and geriatric syndromes, most importantly frailty. in the present study, we aimed to investigate whether there is a difference between tumour characteristics, treatment choices, and outcomes between the younger and older adults. Method The patients who were diagnosed with colorectal carcinoma in our centre between 2010 and 2015 included. Clinicopathological features of tumour, treatment choices and survivals of the patients were recorded. Patients were separated into two groups according to their chronological age. Results The present study included 465 patients, there were 173 patients aged 65 years and older. Clinicopathological features were similar in both groups. Adjuvant chemotherapy was given in similar rates. Whereas combination chemotherapies were preferred in younger patients as first-line therapy, single agents were given to the older group(p-value 0.05). It was observed that 53.2% of the older patients was not treated with any biological treatment (p-value < 0.001). Discussion Geriatric people are underrepresented in clinical trials,because of the presence of the limitations in the older patients. The results of our study revealed older patients with colon cancer patients underwent surgery less than the younger ones, they recieved monotherapy more frequently as first-line chemotherapy, and less frequently targeted therapy. Their mortality was higher. It was shown that decision-making of colon cancer therapy is influenced by age according to our results

Comparison of HER2 status determination methods in HER2 (2+) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH)

WOS: 000416878500007PubMed ID: 29146056HER2 amplification has been demonstrated in 15-25% of invasive breast carcinomas and can be assessed using immunohistochemical and in situ hybridization methods. Here, we compared the accuracy of dual SISH to manual FISH in HER2 (2 +) breast carcinoma and evaluated the feasibility of dual SISH method in routine practice. Sixty HER2 (2 +) consecutive tumor samples diagnosed between January 2009 and February 2013 were selected. Demographic, histological and immunohistochemical features and FISH results were recruited from patient records and compared to dual SISH results. Nine (15%) of the 60 tumor samples were excluded from statistical analysis due to lack of interpretable SISH signals. HER2 staining percentages by immunohistochemistry differed between 20 and 80%. HER2 amplification was shown in 7 (13.7%) and 8 (15.7%) patients by FISH and SISH, respectively. Very good agreement was observed between FISH and SISH methods (kappa value: 0.92). Significant correlation was found between HER2 staining percentage and FISH positivity, in contrast to SISH positivity (p = 0.012 vs. p = 0.069). Our results are consistent with previously reported literature, indicating SISH can be used to determine HER2 status. However, preanalytical and analytical problems may cause inadequate or uncountable signals, making interpretation impossible for the pathologist and highlighting the importance of standardization and quality control programs

Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey

WOS: 000382992100003PubMed ID: 28331745Objective: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the correlations between Recurrence Score (RS) and routine risk factors. Materials and Methods: Ten academic centers across Turkey participated in this prospective trial. Consecutive patients with breast cancer who had pT1-3, pN0-N1mic, ER-positive, and HER2-negative tumors were identified at tumor conferences. Both pre- and post-RS treatment decisions and physician perceptions were recorded on questionnaire forms. Correlations between RS and classic risk factors were evaluated using univariate and multivariate analyses. Results: Ten centers enrolled a total of 165 patients. The median tumor size was 2 cm. Of the 165 patients, 57% had low RS, 35% had intermediate RS, and 8% had high RS, respectively. Multivariate analysis indicated that progesterone receptor (PR) and Ki67 scores were significantly related to RS. Conclusion: Oncotype DX Recurrence Score does not seem to have a significant correlation with the majority of classic risk factors, but it may have a correlation with PR score and Ki67 score.Genomic Health (Inc.; California, USA)Genomic Health (Inc.; California, USA) has provided an educational grant for the genomic testing in this trial

Long-Term Follow-Up of Patients with Male Breast Cancer, Single-Center Experience

WOS: 000469789600002OBJECTIVE Male breast cancer (BC) represents <1% of all BC cases. Our study aimed to define immunohistochemistry (IHC) based surrogate subtype distribution of male BCs, and to define the recurrence pattern and survival among subgroups. METHODS We retrospectively reviewed the medical records of patients with male BC admitted to Ege University School of Medicine, Medical Oncology and Radiation Oncology Clinics between 1998 and 2017. Patient demographics, pathological feature of the primary tumor, adjuvant treatment options, and survival data were analyzed. We defined intrinsic BC subtypes according to estrogen receptor (ER), progesterone receptor (PR), HER-2, and ki-67 status. RESULTS We identified 58 patients with male BC. The median age at diagnosis was 59 years (IQR: 30-78), and median follow-up was 83.7 months. Invasive ductal carcinoma was the most common histology (79.3%). Of the patients, 8.6% presented with stage-4 disease. A total of 24 (41.4%) patients had luminal A-like, 28 (48.3%) had luminal B-like, 2 (3.4%) had HER-2 positive, and 4 (6.9%) had triple negative breast cancer (TNBC). Eighteen deaths were observed during follow-up. The overall survival (OS) and disease-free survival (DFS) rates among BC subgroups were not statistically significant. Median OS was 161 months (95% CI 94.7-228.4)in the patient group. DES was statistically related to initial tumor stage. CONCLUSION The disease onset was found at younger age with more locally advanced setting compared to literature. Luminal predominance was demonstrated. Initial stage but not BC subtypes predict the risk of relapse in patients with male BC

Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 01-06, 2012 -- Chicago, ILWOS: 000318009801881…Amer Soc Clin Onco

Multicentric ipilimumab experience in Turkish patients with metastatic melanoma: MIPI-TURK at 30 months of follow-up.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2013 -- Chicago, ILWOS: 000335419604732…Amer Soc Clin Onco